Opinion|Videos|October 7, 2023
AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma
Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5